CALIGAN PARTNERS LP
Q2 2026 Form 13-F
NEW YORK, NEW YORK
CIK 0001727492
· CRD 289887
· SEC-registered investment adviser
$2.1B Reported Value Total
CALIGAN PARTNERS reports 8 total accounts under management (AUM). There are 8 discretionary accounts valued at $1,299,735,339, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
8 funds
· $1.1B gross asset value
Hedge Fund: $1.1B
Source: Form ADV filed 2026-10-30
Reported value
$2.1B
Quarter over quarter
+45.9%
Holdings
25
Top-10 concentration
80.9%
Key People
Form ADV owners & control persons
David Edward Johnson
PARTNER / LIMITED PARTNER
Tiffany Crowley
CHIEF FINANCIAL OFFICER/CHIEF COMPLIANCE OFFICER
Sarah Bates Johnson
TRUSTEE
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2026 13F record
Q2 2026 13F filing summary
| Period of report | June 30, 2026 |
|---|---|
| Filed | August 14, 2026 |
| Form | 13F-HR |
| Reported value | $2.1B |
| Positions | 25 |
| Change in reported value | +41.5% |
| New positions | 5 |
| Exited positions | 4 |
| Position turnover | 31.0% |
| Top-10 concentration | 80.9% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
25 | $2.1B |
|
Q1 2026 13F
Filed May 15, 2026
|
24 | $1.5B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
20 | $1.2B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
16 | $763.5M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
16 | $520.2M |
|
Q1 2025 13F
Filed May 15, 2025
|
16 | $479.2M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
14 | $394.9M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
12 | $315.5M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
13 | $428.0M |
|
Q1 2024 13F
Filed May 13, 2024
|
12 | $378.3M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
11 | $296.5M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
12 | $217.8M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
12 | $177.8M |
|
Q1 2023 13F
Filed May 15, 2023
|
11 | $143.4M |
|
Q4 2022 13F
Filed Feb 15, 2023
|
11 | $120.2M |
Top 20 holdings · Q2 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | LQDA LIQUIDIA CORPORATION | $647.3M | 30.45% |
| 2 | RVMD REVOLUTION MEDICINES INC | $367.4M | 17.28% |
| 3 | ABVX ABIVAX SA | $207.6M | 9.77% |
| 4 | PCVX VAXCYTE INC | $127.2M | 5.99% |
| 5 | EXEL EXELIXIS INC | $84.5M | 3.98% |
| 6 | TNGX TANGO THERAPEUTICS INC | $78.2M | 3.68% |
| 7 | AVTX AVALO THERAPEUTICS INC | $58.5M | 2.75% |
| 8 | XENE XENON PHARMACEUTICALS INC | $53.7M | 2.53% |
| 9 | ADMA ADMA BIOLOGICS INC | $47.9M | 2.25% |
| 10 | RVMD C REVOLUTION MEDICINES INC | $47.2M | 2.22% |
| 11 | LBRX LB PHARMACEUTICALS INC | $46.7M | 2.2% |
| 12 | IMCR IMMUNOCORE HLDGS PLC | $43.9M | 2.06% |
| 13 | VRDN VIRIDIAN THERAPEUTICS INC | $40.3M | 1.9% |
| 14 | VOR VOR BIOPHARMA INC | $35.4M | 1.67% |
| 15 | SABS SAB BIOTHERAPEUTICS INC | $31.1M | 1.46% |
| 16 | IVA INVENTIVA SA | $30.9M | 1.45% |
| 17 | AURA AURA BIOSCIENCES INC | $30.5M | 1.44% |
| 18 | TYRA TYRA BIOSCIENCES INC | $25.8M | 1.21% |
| 19 | OCUP OPUS GENETICS INC | $25.0M | 1.17% |
| 20 | ANIK ANIKA THERAPEUTICS INC | $21.0M | 0.99% |
Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.